AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)
AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)

Balance Sheet ADMP Quote Adamis Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 4 4 17
ShortTermInvest 0 0 0
Cash 4 4 17
AccountReceivab 0 1 1
Inventories 0 1 2
DeferredIncomeT 0 0 0
OtherCurrentAss 0 1 1
TotalCurrentAss 4 7 21
PPE 0 5 8
AccumulatedDepr 0 -1 -1
NetPPE 0 5 7
EquityAndOtherI 0 0 0
Goodwill 0 8 8
IntangibleAsset 8 18 16
OtherLTAssets 0 0 0
TotalNonCurrent 8 31 30
TotalAssets 12 38 51
ShortTermDebt 0 4 2
AccountsPayable 0 2 3
TaxesPayable 0 0 0
AccruedLiabilit 1 2 3
DeferredRevenue 0 0 0
OtherCurrentLia 2 0 0
TotalCurrentLia 3 9 9
Debt 0 3 3
DeferredTaxesLi 0 1 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 4 3
TotalLiabilitie 3 13 12
CommonStock 0 0 0
AdditionalPaidI 78 114 154
RetainedEarning -69 -88 -114
AccumulatedOthe 0 0 0
TotalStockholde 9 25 40
TotalLiabilitie 12 38 51
Adamis Pharmaceuticals Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adamis Pharmaceuticals Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.